Gabapentin Capsule
Product Images NDC 60760-926

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60760-926). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

926-60 (Gabapentin 60760 926 60)

GABAPENTIN Capsules, USP 100 mg label displaying quantity of 60 capsules. The label includes the NDC 60760-926-60 and notes it is manufactured by Granules India Limited in Hyderabad, India. Packaged by St. Mary's Medical Park Pharmacy in Oro Valley, AZ. The label also states storage instructions at controlled room temperature (15°-30°C) and has a barcode with associated data matrix.*

FDA Label Image

Gaba-fig1 (Gaba Fig1)

A line graph showing mean pain scores over 8 weeks comparing placebo and gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin's pain scores decline over time, while placebo scores remain relatively stable.*

FDA Label Image

Gaba-fig2 (Gaba Fig2)

A line graph depicting mean pain scores over 7 weeks for placebo and two gabapentin dosages (1800 mg/day and 2400 mg/day). The x-axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin groups show a decrease in pain scores compared to placebo over time.*

FDA Label Image

Gaba-fig3 (Gaba Fig3)

A bar chart illustrating the proportion of responders (patients with at least 50% reduction in pain score) at the endpoint in controlled PHN studies. It compares placebo (PBO) and Gabapentin (GBP) at doses 1800, 2400, and 3600 mg across two studies. The chart shows higher response rates for Gabapentin versus placebo, with significance levels indicated by asterisks.*

FDA Label Image

Gaba-fig4 (Gaba Fig4)

A scatter plot showing percentage difference versus daily dose (mg) for Gabapentin from three studies labeled a, b, and c. The x-axis represents daily dose in mg ranging from 600 to 1800, while the y-axis shows percentage difference from 1 to 22%. Study a is represented with black squares, study b with gray squares, and study c with white squares. Data points from the three studies vary across doses and percentage differences, illustrating comparison among studies.*

FDA Label Image

Gaba-formula (Gaba Formula)

A text panel displaying the formula for calculating creatinine clearance (CLCr), which includes age, weight, serum creatinine level, and a multiplication factor of 0.85 for female patients. The formula is shown as a mathematical expression dividing (140 minus age in years, multiplied by weight in kg) by (72 times serum creatinine in mg/dL).*

FDA Label Image

Gaba-structure (Gaba Structure)

Chemical structure of gabapentin showing the cyclohexane ring with attached amino and carboxylic acid functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.